HL187 / Daewoong Pharma, HanAll Biopharma - LARVOL DELTA

Hanall Biopharma, 2 Candidates for Immune Oncology Drugs 'Cut Off' [Google translation] (Medi-consumer News) - "HanAll Biopharma has decided to discontinue the development of its anticancer antibody drugs 'HL186' and 'HL187'. However, it appears that they have not completely given up on the research, as they are leaving room for the development to continue in a different form than the one currently under development...'Due to the recent increase in cases of global competitors' failure to prove efficacy and clinical discontinuation of new immune-oncology antibody drugs.'....However, HanAll Biopharma left open the possibility of resuming development of HL186 and HL187."

Discontinued • Oncology

HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update (PRNewswire) - "Novel monoclonal antibodies that respectively target TIM-3 and TIGIT, for the treatment of cancer developed in collaboration with Daewoong Pharmaceutical Co. HanAll is continuing with the pre-clinical development of HL187 and plans to submit IND for phase 1 in 2023. HL186 is currently in the discovery phase."

IND • Oncology

HanAll Biopharma Reports Third Quarter 2021 Results (PRNewswire) - "HL186/HL187 (novel immune-oncology therapies): HL186 and HL187 projects are novel immuno-oncology antibodies that target TIM-3 and TIGIT, respectively, developed in collaboration with Daewoong Pharmaceutical. Both programs are at preclinical stage. The companies aim to develop differentiated immune checkpoint inhibitors with better efficacy and higher response rates for patients with cancer."

Preclinical • Oncology